Alzheimer's Anti-Amyloid Drugs: Review Sparks Debate
A sweeping review of seven anti-amyloid Alzheimer's drugs finds negligible benefit, but researchers push back hard on the methodology.
13 articles tagged "Clinical Research"
A sweeping review of seven anti-amyloid Alzheimer's drugs finds negligible benefit, but researchers push back hard on the methodology.
Nearly 30% of clinical trials required to report results never submitted data to ClinicalTrials.gov, prompting FDA enforcement letters in April 2026.
Eight years after the 2018 Lancet Series, preconception health has evolved conceptually but faces real barriers to full clinical implementation.
The FDA is requesting expanded statutory authority over direct-to-consumer drug ads in its FY2027 budget, targeting misleading pharmaceutical promotions.
The BMJ has retracted the PREVENT-TAHA8 phase 3 trial on mesenchymal stem cells for heart failure due to data integrity and enrollment concerns.
Insmed's Arikayce met primary endpoints in a phase 3 trial for treatment-naive MAC lung infection patients, improving symptoms and culture conversion rates.
Stroke survivors face 1.5x higher fall risk. New Australian trial evidence supports home-based, individualized programs to reduce falls in this vulnerable group.
New evidence challenges single eGFR measurements in CKD, suggesting GFR decline trajectory is more clinically actionable than point-in-time precision.
Analysts warn Iran conflict could disrupt pharma supply chains via Strait of Hormuz, while Pfizer's Lyme disease vaccine shows promise in Phase 3 trials.
A Lancet commentary argues surgical technique is a key variable in lung cancer outcomes, urging rigorous trial design to evaluate minimally invasive approaches.
Aldeyra Therapeutics faces FDA scrutiny amid short-seller pressure as its regulatory decision window approaches. What clinicians need to know in 2026.
Global ASD and ADHD diagnoses have surged over two decades. Evidence suggests this reflects correcting historic underdiagnosis, not a true prevalence increase.
The FDA is cutting back on public advisory committee meetings as contested drug approval decisions mount, raising transparency concerns for patients nationwide.